SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ELTP

Elite Pharmaceuticals Inc /Nv/ (OTC:ELTP)

US · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - Specialty & Generic
$0.32+$0.00 (-1.20%)
 
Market cap
$345M
Insider Score
Health Score
Listed since
Feb 24, 2000
Market Cap$344.82M-39.6%
Revenue (ttm)$144.77M+17.8%
Net Income$60.28M+333.0%
EPS$0.04+576.8%
Shares Out1.08B
PE Ratio5.70
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume155,111
Open$0.32
Previous Close$0.32
Day's Range$0.32 - $0.34
52-Week Range$0.21 - $0.55
Beta0.41
Analystsn/a
Price Targetn/a
Earnings Daten/a
-1.20% (1D)
No price history available.

About ELTP

Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals. The company's extensive product line includes drugs that it either owns, licenses, or produces through contract manufacturing. This portfolio features a variety of generic and oral-dose pharmaceutical products designed to address diverse medical needs. For instance, it offers Phentermine HCl 37.5mg tablets, marketed under the Adipex-P brand, and Phendimetrazine Tartrate 35mg tablets, known as Bontril, both utilized in bariatric medicine. Its offerings also extend to Naltrexone HCl 50mg tablets (Revia brand) for pain management, and Isradipine 2.5mg and 5mg capsules for cardiovascular conditions. Elite Pharmaceuticals further supplies various strengths of Oxycodone HCl immediate release tablets (5mg, 10mg, 15mg, 20mg, and 30mg) under the Roxycodone brand for pain relief, as well as Trimipramine Maleate Immediate Release antidepressant capsules (Surmontil brand). For central nervous system disorders, the company provides Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets, commonly associated with the Adderall brand. Additionally, its products include Dantrolene Sodium capsules (Dantrium brand) for muscle relaxation, SequestOX (an immediate-release Oxycodone formulation combined with Naltrexone), Loxapine Succinate capsules (Loxapine brand) for antipsychotic treatment, and a combination of Acetaminophen and Codeine Phosphate for managing mild to moderate pain, alongside various antibiotic products. Beyond its own product portfolio, Elite Pharmaceuticals also undertakes contract manufacturing of controlled-release products for external parties, covering therapeutic areas such as pain, allergies, bariatrics, and infections. The company is actively engaged in developing a new generation of opioid products specifically engineered to deter abuse. Established in 1997, Elite Pharmaceuticals, Inc. maintains its corporate headquarters in Northvale, New Jersey.

Address
165 Ludlow Avenue, Northvale, NJ, 07647, US
Market Cap
345 million
Employees
65
Industrial Classification
Drug Manufacturers - Specialty & Generic

Elite Pharmaceuticals Inc /NV/ Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
35th Percentile Overall Score
ELTP InsiderScore:62 / 99

Elite Pharmaceuticals Inc /NV/ scored higher than 35% of companies evaluated by InsiderBuying, and ranked 53rd out of 102 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Elite Pharmaceuticals Inc /NV/ bought $26.0K of stock across 1 purchase in the last 90 days, the largest of them $26.0K.

Stake Increase

The average purchase added about 3% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$496.00K
Bought
$34.59K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Strong
From ELTP’s reported statements · Q3 2026 (trailing 12 months)
1 Day
-1.20%
5 Days
-0.81%
1 Month
+29.29%
6 Months
-7.38%
1 Year
-39.61%

$ELTP stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ELTP holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ELTP's directors and management

Net Shares Purchased by Insiders−800k−400k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ELTP Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ELTP patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ELTP from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from ELTP’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
71% of score
41.15
Analyst Ratings
No data yet
—
News & Sentiment
29% of score
65

News check: Q2 2027 earnings show 10% revenue growth year-over-year with positive stock reaction; solid operational performance without major negative catalysts.

Recent Insider Activity

Buys
2
Sells
1
Buy Value
$34.59K
Distinct Buyers
1

Insider Score Trend Over Time

+35.1 since Sep 24
0255075100Sep 24 — Insider Score 24.1Sep 25 — Insider Score 57.0Sep 26 — Insider Score 56.6Sep 27 — Insider Score 56.9Sep 28 — Insider Score 57.0Sep 29 — Insider Score 56.5Sep 30 — Insider Score 56.2Oct 1 — Insider Score 56.8Oct 2 — Insider Score 38.0Oct 3 — Insider Score 56.5Oct 4 — Insider Score 56.7Oct 5 — Insider Score 56.8Oct 6 — Insider Score 56.2Oct 7 — Insider Score 54.8Oct 8 — Insider Score 54.6Oct 9 — Insider Score 54.3Oct 10 — Insider Score 53.8Oct 11 — Insider Score 55.3Oct 12 — Insider Score 55.4Oct 13 — Insider Score 55.2Oct 14 — Insider Score 55.1Oct 15 — Insider Score 55.0Oct 16 — Insider Score 54.8Oct 17 — Insider Score 54.8Oct 18 — Insider Score 55.2Oct 19 — Insider Score 79.1Oct 20 — Insider Score 79.0Oct 21 — Insider Score 78.9Oct 22 — Insider Score 78.8Oct 23 — Insider Score 78.9Oct 24 — Insider Score 78.9Oct 25 — Insider Score 78.6Oct 26 — Insider Score 78.4Oct 27 — Insider Score 78.4Oct 28 — Insider Score 78.3Oct 29 — Insider Score 77.8Oct 30 — Insider Score 76.6Oct 31 — Insider Score 76.2Nov 1 — Insider Score 76.4Nov 2 — Insider Score 76.2Nov 3 — Insider Score 75.3Nov 4 — Insider Score 74.5Nov 5 — Insider Score 73.7Nov 6 — Insider Score 72.7Nov 7 — Insider Score 72.2Nov 8 — Insider Score 72.6Nov 9 — Insider Score 72.9Nov 10 — Insider Score 71.3Nov 11 — Insider Score 70.6Nov 12 — Insider Score 70.2Nov 13 — Insider Score 68.6Nov 14 — Insider Score 67.5Nov 15 — Insider Score 68.0Nov 16 — Insider Score 67.0Nov 17 — Insider Score 63.3Nov 18 — Insider Score 62.0Nov 19 — Insider Score 61.0Nov 20 — Insider Score 59.6Nov 21 — Insider Score 59.0Nov 22 — Insider Score 59.2Sep 24Oct 23Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.